Given the fact that immune-checkpoint inhibitors are approved as first-line standard treatment for recurrent and metastatic HNSCC patients, abemaciclib may provide a perspective for the majority of patients that do not respond to PD-1 antibodies. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.